Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down – Here’s What Happened

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price gapped down prior to trading on Monday . The stock had previously closed at $17.63, but opened at $16.97. Theravance Biopharma shares last traded at $17.04, with a volume of 771,977 shares.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. JonesTrading reaffirmed a “hold” rating on shares of Theravance Biopharma in a report on Monday. Weiss Ratings downgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 27th. HC Wainwright boosted their price target on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Zacks Research lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. Finally, Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. One investment analyst has rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $21.40.

Theravance Biopharma Stock Down 2.2%

The stock’s 50 day moving average is $16.56 and its 200-day moving average is $17.30. The company has a market cap of $888.77 million, a PE ratio of 7.84 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. On average, analysts anticipate that Theravance Biopharma, Inc. will post 1.54 EPS for the current fiscal year.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the sale, the senior vice president directly owned 232,457 shares of the company’s stock, valued at $3,809,970.23. This trade represents a 5.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TBPH. Empowered Funds LLC purchased a new position in shares of Theravance Biopharma during the 1st quarter worth about $900,000. Bank of America Corp DE raised its holdings in shares of Theravance Biopharma by 78.2% in the first quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock worth $3,070,000 after buying an additional 82,978 shares during the period. California State Teachers Retirement System lifted its stake in shares of Theravance Biopharma by 1,649.4% during the 1st quarter. California State Teachers Retirement System now owns 40,761 shares of the biopharmaceutical company’s stock worth $662,000 after acquiring an additional 38,431 shares during the last quarter. Quantinno Capital Management LP boosted its holdings in Theravance Biopharma by 32.9% during the 1st quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 4,463 shares during the period. Finally, Rangeley Capital LLC bought a new position in Theravance Biopharma in the 1st quarter valued at $1,672,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.